Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Cannot have received: lenvatinib (lenvatinib)

Prior treatment with lenvatinib

Cannot have received: anti-PD-1 therapy

Prior treatment with anti-programmed cell death-1(PD)-1

Cannot have received: anti-PD-L1 therapy

Prior treatment with anti-PD-L1

Cannot have received: checkpoint inhibitor

any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways

Cannot have received: radiation therapy

Exception: No prior radiation therapy to the vagina, pelvis, or abdomen will be allowed.

No prior radiation therapy to the vagina, pelvis, or abdomen will be allowed.

Cannot have received: investigational agent

Patients who are currently in or have participated in a study of an investigational agent or used an investigational device within 4 weeks of the first dose of study treatment.